Cell line · CVCL_3505
Papers16
8 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 16 of 16
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Spatially Resolved Metabolomics of Optimal Cutting Temperature (OCT) Compound-Embedded Tumors. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. | NPJ Vaccines | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. | Mol Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic discovery of chemical probes that perturb protein complexes in human cells. | Mol Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| The CIt protocol: A blueprint to potentiate the immunogenicity of immunoproteasome-reprogrammed mesenchymal stromal cells. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. | Nat Metab | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. | Cell Metab | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. | Cancer Cell | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial Priming by CD28. | Cell | 2017 | Its Methods give the RRID and name the line | PubMed | |
| Introduction of soluble protein into the class I pathway of antigen processing and presentation. | Cell | 1988 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3505/papers